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Summary The distribution of phosphoglycerate mutase (EC 5.4.2.1, PGM), 2,3-bisphosphoglycerate phosphatase (EC 3.1.3.13, BPGP) and
creatine kinase (EC 2.7.3.2, CK) activity and isoenzymes in various regions of adult human brain and in brain tumours (astrocytomas,
anaplastic astrocytomas, glioblastomas and meningiomas) has been determined using electrophoresis. PGM and cytosolic CK exist in
mammalian tissues as three isoenzymes that result from the homodimeric and heterodimeric combinations of two subunits [types M (muscle)
and B (brain)] coded by separated genes. In addition, a dimeric from and an octameric form of mitochondrial CK exist in mammals. Type BB-
PGM was the major PGM isoenzyme found in normal brain, although type MB-PGM and type MM-PGM were also detected. All brain tumours
possessed lower PGM activity than normal brain, and meningiomas showed higher BPGP activity. In astrocytic tumours, the proportion of
type MB- and type MM-PGM decreased, and in meningiomas these isoenzymes were not detected. Type BB-CK and mitochondrial CK
were the only CK isoenzymes detected in normal brain. Astrocytomas possessed lower CK activity than anaplastic astrocytomas and
glioblastomas and, in addition, tended to possess lower CK content than normal brain. No qualitative changes of the normal CK isoenzyme
pattern were observed in the tumours.
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Most isoenzyme transitions that occur in neoplastic tissues repre-
sent a shift from a differentiated to an undifferentiated pattern. The
transitions to a more differentiated pattern are much less frequent
and involve a great alteration in the control of gene expression.
Omenn and co-workers (Omenn and Cheung, 1974; Omenn and
Hermodson, 1975) described in human brain tumours a transition
in the phosphoglycerate mutase phenotype from the normal brain
pattern to a more differentiated muscle-type pattern that correlated
with the degree of malignancy of the tumours and that could
constitute a good brain tumour marker. As the series of tumours
studied by Omenn and Cheung (1974) and Omenn and
Hermodson (1975) was small and the distribution of phospho-
glycerate mutase isoenzymes in human brain was poorly known,
the present study was undertaken. In addition to phosphoglycerate
mutase, we have determined creatine kinase, which possesses
isoenzymes with a tissue distribution similar to those ofphospho-
glycerate mutase.
Phosphoglycerate mutase (D-phosphoglycerate 2,3-phospho-
mutase, EC 5.4.2.1, PGM) is a glycolytic enzyme present in
mammalian cells in substantial amounts that catalyses the intercon-
version of 3-phosphoglycerate and 2-phosphoglycerate in the pres-
ence of the cofactor 2,3-bisphosphoglycerate. In addition to the
mutase activity, it possesses 2,3-bisphosphoglycerate phosphatase
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activity stimulated by 2-phosphoglycolate (for a review, see
Fothergill-Gilmore and Watson, 1989). Creatine kinase (ATP:
creatine N-phosphotransferase, EC 2.7.3.2, CK) is an ubiquitous
enzyme that functions in the transfer ofenergy from the mitochon-
dria to the cytosol and thatcatalyses the reversible transphosphoryl-
ation reaction between ATP and creatine, generating ADP and
phosphocreatine (for a review, see Bessman and Carpenter, 1985).
In mammals three isoenzymes ofPGM and three cytosolic isoen-
zymes ofCK have been detected that result, in both cases, from the
homodimeric and the heterodimeric combinations of two different
subunits coded by separate genes and designated M (muscle) and B
(brain). In early fetal life, type BB-PGM and type BB-CK are the
only forms present. During myogenesis the isoenzyme phenotypes
undergo transition, type BB-PGM and type BB-CK being replaced
by the MM forms through the MB isoenzymes. In adult mammals,
skeletal muscle contains almost exclusively type MM-PGM and
type MM-CK, whereas type BB-PGM and type BB-CK are found
in most types of tissue. Only in heart are the three PGM and CK
isoenzymes present in substantial amounts. Mammalian tissues
also express two mitochondrial CK (Mt-CK) subunits ('ubiquitous'
Mt-CK and 'sarcomeric' or striated muscle-specific Mt-CK) that
form octameric and dimeric molecules (forreviews, see Wallimann
et al, 1992; Wyss et al, 1992; Carreras and Gallego, 1993; Durany
and Carreras, 1996). In addition to PGM isoenzymes, in mammals
there are other enzymes that have 2-phosphoglycolate-stimulated
BPGP activity. One such enzyme is the 2,3-bisphosphoglycerate
synthase phosphatase or 2,3-bisphosphoglycerate mutase (EC
5.4.2.4, BPGM), which is a homodimer of a subunit that possesses
great homology with PGM subunits. Two other enzymes are
heterodimers resulting from the combination of a BPGM subunit
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with a PGM subunit of either type M or type B (for review, see
Carreras and Gallego, 1993).
Omenn and co-workers detected only type BB-PGM in human
brain (Omenn and Cheung, 1974; Omenn and Herdmodson,
1975), but we have found type MB- and MM-PGM in rat and pig
brain, and the hybrid BPGM-type B-PGM in pig brain (Carreras
et al, 1981; Mezquita and Carreras, 1981; Mezquita et al, 1981;
Durany and Carreras, 1996). Type BB-CK is the major CK
cytosolic isoenzyme found in mammalian brain. Whether brain
tissue contains significant amounts oftype MB-CK and type MM-
CK in addition to ubiquitous Mt-CK is controversial (Wallimann
et al, 1992; Wyss et al, 1992).
In the present study, we have determined the distribution of the
total PGM, BPGP and CK activities and isoenzymes in various
regions of human brain at different ages and in brain tumours to
identify their changes in neoplastic tissues as a first step to study
the alterations of the expression of PGM and CK genes. On the
distribution ofPGM isoenzymes in brain tumours, only the reports
by Omenn and Cheung (1974) and Omenn and Herdmodson
(1975) have been published. In addition, there is little information
available on CK isoenzymes in brain tumours. Several reports
have been published on CK isoenzymes in embryonal brain
tumours but, to our knowledge, only three reports exist on the CK
isoenzymes phenotype in astrocytic tumours (Rona et al, 1972;
Omenn and Cheung, 1974; Tsung, 1983).
MATERIALS AND METHODS
Materials
Enzymes, substrates, cofactors and biochemicals were purchased
from either Boehringer (Mannheim, Germany) or Sigma (St Louis,
MI, USA). CK-MB DS reaction mixture (cat no. 1.12948) from
Merck (Darmstadt, Germany) was used as the source of M-CK
antibodies. f-Mercaptoethanol was from Merck (Darmstad,
Germany). Bovine serum albumin was from Calbiochem (LaJolla,
CA, USA). Other chemicals were reagent grade. Agar noble was
from Difco Laboratories (Detroit, MI, USA). Agarose gels were
from Ciba-Coming (Palo Alto, CA, USA) and cellulose acetate
strips were from Helena Laboratories (Beaumont, TX, USA).
Tissue samples
Brain samples were obtained from the Neurological Tissue Bank,
'Hospital Clinic', University of Barcelona, Spain. Samples from
cerebral cortex (superior frontal gyrus), nucleus caudatus (ante-
rior), cerebral white matter (centrum semiovale) and cerebellar
hemisphere were used as control. The patients were aged 23, 41,
43, 44, 48, 52, 59, 60, 65, 66, 67, 74, 82 and 95 years, of whom
seven were men and seven were women. The post-mortem delay
was 1-12 h. Tumour tissues were obtained from material used for
biopsy during surgery. Tumours were supratentorial and were clas-
sified, according to the WHO brain tumour classification (Kleines
et al, 1993), as low-grade astrocytomas (four patients), anaplastic
astrocytomas (six patients), glioblastomas (11 patients) and
meningiomas (six patients). The mean age ofthe patients suffering
from the tumours was 57.3 years, ranging from 45 to 72 years.
Skeletal muscle and heart samples were obtained during autopsy
within 24 h after death.
Tissue extraction
Tissue extracts were prepared by homogenization in three volumes
(w/v) of cold 20 mM Tris-HCl buffer, pH 7.5, containing 1 mM
EDTA and 1 mM P-mercaptoethanol with a Polytron homogenizer
(Lucerne, Switzerland) (position 5, 20 s). Cellular debris was
removed by centrifugation at 4°C for 30 min at 12 500g, and the
supernatants were used for the assay of enzyme activities and
isoenzyme distribution.
Enzyme and protein assays
All enzymatic activities were measured at 30°C. CK activity was
determined by coupling the formation ofATP from ADP and phos-
phocreatine with the hexokinase- and glucose 6-phosphate dehy-
drogenase-catalysed reactions, as previously reported (Joseph et al,
1997). PGM activity was determined by coupling the
formation of2-phosphoglycerate from 3-phosphoglycerate with the
enolase-, pyruvate kinase- and lactate dehydrogenase-catalysed
reactions (Beutler, 1975), as previously described (Durany and
Carreras, 1996). BPGP activity was assayed by measuring the
Table 1 Levels of PGM activity in various regions of normal human brain
Age (years)
Brain region 23 41 43 48 52 60 65 67 74 82 95
Cortex
U g-l a 21 19 20 30 20 18 20 15 22 27 20
Umg-1 a 1.1 2.3 1.1 1.6 1.9 1.1 1.8 1.0 1.4 1.2 1.4
Nucleus caudatus
Ug91 23 29 21 24 15 18 22 16 23 26 25
U mg-' 1.1 1.9 1.2 1.3 1.5 1.4 1.5 1.1 1.6 1.5 1.2
White matter
Ug-1 18 24 29 26 13 13 18 17 22 22 18
U mg-1 1.1 1.8 2.0 1.5 1.1 1.0 1.7 1.5 1.8 1.2 1.4
Cerebellum
Ug-1 25 36 44 42 22 - 52 16 16 29 26
U mg-1 1.2 3.0 3.1 1.5 1.7 - 1.9 1.3 1.3 1.0 1.4
aActivity is expressed as units per g of wet tissue and as units per mg of extracted protein.
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Figure 1 Electrophoretograms of PGM isoenzymes in extracts of various regions of normal human brain. (A) Patient aged 23 years. (B) Patient aged
41 years. (C) Patient aged 82 years. (D) Patient aged 95 years. 1, Cortex; 2, white matter; 3, nucleus caudatus; 4, cerebellum
Table 2 Distribution of PGM isoenzymes (MM, MB, BB) in various regions of normal human brain
Age (years)
Brain region 23 41 48 60 65 67 71 82 95
Cortex
MMa 0 4 0 0 0 0 1 4 1
MBa 0 4 9 4 14 6 8 10 9
BBa 100 92 91 96 86 94 91 86 90
Nucleus caudatus
MM 0 2 2 0 0 0 3 5 5
MB 0 16 32 5 5 11 25 16 20
BB 100 82 66 95 95 89 72 79 75
White matter
MM 0 1 1 0 3 0 2 2 7
MB 0 24 14 8 25 15 14 11 30
BB 100 75 85 92 72 85 84 87 63
Cerebellum
MM 1 1 4 - 3 0 2 3 5
MB 13 16 36 - 23 23 7 24 31
BB 86 83 60 - 74 77 91 73 64
aThe results are expressed as a percentage of the total PGM activity on electrophoresis.
appearance of inorganic phosphate from 2,3-bisphosphoglycerate,
as previously reported (Durany et al, 1997). Enzyme activities were
expressed as U g-' wet tissue and as U mg-' protein (1 U = 1 g.mol
substrate converted permin). Protein was determinedby the method
ofBradford (1976), using bovine serum albumin as a standard.
Isoenzyme analysis
The methods previously described were used to evaluate PGM
isoenzymes by cellulose acetate electrophoresis (Durany and
Carreras, 1996) and CKisoenzymes by agarose gel electrophoresis
(Joseph et al, 1997).
Ion-exchange chromatography
High-resolution ion-exchange fast-liquid chromatography (FPLC
system and HR 5/5 Mono Q or Mono P columns from Pharmacia)
was used. The column was equilibrated with cold Tris-HCl buffer
(50 mm Tris, 1 mM EDTA, 1 mm f-mercaptoethanol, pH 8.3). The
tissue extract (1 ml) was filtered through a column of Sephadex
G-25 fine (24 x 1 cm) equilibrated with the same buffer, and a
volume of 2 ml containing 8 mg of protein was injected into the
FPLC column. Elution was performed with a 30-ml linear gradient
of0-500 mm sodium chloride in the equilibrating buffer. At a flow
rate of 1 ml min-', 0.25 ml fractions were collected and analysed
for CK activity.
Inhibition of M-CK subunit
Ten microlites of muscle extract and 25 gl of brain extract
(containing 10 Uml-I and 90 Uml-I respectively) were mixed with
90 ,ul and 25 p1 ofthe solution containing M-CK antibodies. After
3 min ofincubation at 30°C, the mixture was cooled in an ice bath,
and the CK isoenzymes were determined as described above.
Statistical analysis
The Kruskal-Wallis test (non-parametric ANOVA) was used to
compare enzyme activity levels among different tumour groups
and control. The differences between groups were located using
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Figure 2 Electrophoretograms of PGM isoenzymes in extracts of human brain tumours. Lane 1, heart; lanes 3 and 5, astrocytomas; lanes 2, 4, 6 and 12,
anaplastic astrocytomas; lanes 7-11, glioblastomas; lanes 13-16, meningiomas
Table 3 Total PGM activity and isoenzymes in human brain tumours
Tumour Survival period Total PGM activity PGM isoenzymes (percent of total activity)
Case no. (months)
U g-' Tissuea U mg-' Proteinb MM MB BB
Astrocytoma
1
2
3
Mean ± s.e.m.
Median (range)
Anaplastic astrocytoma
1
2
3
4
5
6
Mean ± s.e.m.
Median (range)
Glioblastoma
1
2
3
4
5
6
7
8
9
10
11
Mean ± s.e.m.
Median (range)
96
c
108
26
25
7
19.3 ± 6.1
25 (7-26)
23
26
69
20
36
48
13
18
6
5
8
22
1.3
0.5
0.3
0.7 + 0.3
0.5 (0.3-1.3)
0.3
1.1
0.2
0.4
0.5
0.9
12.0±2.7 0.56±0.1
11.0 (5-22) 0.45 (0.2-1.1)
10
12
9
13
11
9
8
15
11
14
13
8
22
5
12
16
12
15
13
11
9
14
1.1
0.6
0.3
0.6
0.7
0.4
0.6
0.3
0.2
0.3
0.5
12.4 ± 1.3 0.5 ± 0.07
12 (5-22) 0.5 (0.2-1.1)
16
10
9
11
16
24
0.7
0.7
0.3
0.5
0.9
0.9
14.3 ± 2.2 0.67 0.09
19 (9-26) 0.7 (0.3-0.9)
22.0 ± 1.5 1.5 ± 0.1
21 (13-30) 1.5 (1-2.3)
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0
0
0
0+0
0 (0-0)
5
0
1
0
1 ±0.9
0 (0-5)
2
0
8
0
2
4
0
6
1
3±0.9
2 (0-8)
2
3
0
2 ±0.9
2 (0-3)
19
0
6
3
ND
5
7± 3.2
5 (0-19)
ND
21
8
20
4
3
ND
13
13
18
1
11 ±2.5
13 (1-21)
98
97
100
98 + 0.8
98 (97-100)
76
100
93
97
95
92 ± 4.2
93 (10-97)
77
92
72
96
95
83
87
76
98
86 ± 3.2
87 (72-98)
Meningioma
1
2
3
4
5
6
Mean s.e.m.
Median (range)
Control tissue,
Mean ± s.e.m.
Median (range)
0
0
0
0
0
0
0±0
0 (0-0)
1 ± 0.45
1 (0-4)
0
0
0
0
0
0
0±0
0 (0-0)
13 ± 3.2
9 (4-32)
100
100
100
100
100
100
100 -0
100 (100-100)
86 ± 3.3
91 (66-96)
aControl vs glioblastoma, P < 0.001; control vs meningioma, P < 0.05. bControl vs anaplastic astrocytoma, glioblastoma and meningioma, P < 0.001;
control vs astrocytoma, P < 0.01. cAfter 10 years offollow-up, patient is still surviving and no-recurrence has been registered. dFifteen specimens
from patients aged 41-60 years with normal brains (cortex, white matter and nucleus caudatus).
c
c
c
c
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the Mann-Whitney U-Test. All P-values are two-tailed. Values are
reported as mean ± s.e.m. and as median and range. Data were
analysed by Instat statistical software.
RESULTS
Distribution of total PGM activity in normal brain and in
tumours
Table 1 summarizes the levels of total PGM activity in various
regions of human brain at different ages. As shown, wide vari-
ability was found, but up to 65 years of age the PGM activity per
gram of wet tissue detected in cerebellum was somewhat higher
than the PGM activity found in the other corresponding brain
regions. This difference was not observed when the PGM activity
was expressed per mg ofprotein.
Table 3 presents the levels oftotal PGM activity in astrocytomas,
anaplastic astrocytomas, glioblastomas and meningiomas. The
comparison of the levels of PGM activity per mg of extracted
protein in brain tumours and in control tissues shows that all groups
of tumours possess lower PGM content than the normal brain
(P < 0.01); this is also observed when the levels of PGM activity
are expressed per gram of wet tissue, however only the differences
between control vs glioblastoma and control vs meningioma are
statistically significant. Among the astrocytic tumours, the levels of
PGM activity tend to decrease with malignancy, although the
differences observedbetween the various groups oftumours are not
statistically significant.
Distribution of PGM isoenzymes in normal brain and in
tumours
PGM isoenzymes were determined in extracts of the various
regions ofhuman brain by cellulose acetate electrophoresis. Figure
1 shows some ofthe electrophoretograms and Table 2 summarizes
the results obtained. As shown, type BB-PGM was the major PGM
isoenzyme found in human brain, although the PGM isoenzymes
that possess the type M-PGM subunit were also detected. In all
specimens, the proportion of type MB-PGM was higher than that
ofMM-PGM.
Figure 2 presents the PGM electrophoretograms ofsome tumour
specimens, and Table 3 summarizes the dataobtained on the distri-
bution of PGM isoenzymes in brain tumours. As shown, in the
astrocytic tumours, particularly in benign astrocytomas, the
proportion of MM- and MB-PGM isoenzymes tended to be lower
than in control brain tissue, although the differences observed were
not statistically significant. No PGM isoenzymes containing the
type M subunit were found in meningiomas.
Table 4 Distribution of BPGP activity in normal human brain and in tumours
Total BPGP
Tissue mU g-' Tissuea mU mg-' Proteinb PGM/BPGP
Normalbrain c
Cortex
Mean±s.e.m. 158±32 19±8.9 175
Median (range) 120 (70-360) 6(5-87)
Nucleus caudatus
Mean±s.e.m. 116±13 7±0.7 210
Median (range) 100(60-180) 7(4-10)
White matter
Mean±s.e.m. 123±17 12±2.5 163
Median (range) 120 (60-190) 10 (6-30)
Cerebellum
Mean±s.e.m. 156± 18 11±2.4 216
Median (range) 165 (80-230) 10 (3-25)
Tumours
Astrocytoma
Mean ± s.e.m. 125 ± 25 4.3 ± 0.3 154
Median (range) 124 (99-150) 4.3 (4-4.7)
Anaplastic astrocytoma
Mean ±s.e.m. 81±5 3.9±0.6 148
Median (range) 84 (60-90) 3.2 (2.5-5.8)
Glioblastoma
Mean ± s.e.m. 99.8 ± 11 4.2 ± 0.7 124
Median (range) 94 (70-150) 3.7 (2-7)
Meningioma
Mean ± s.e.m. 294 ± 34 13.8 + 1.4 49
Median (range) 30 (180-390) 13 (10-18)
Control tissued
Mean±s.e.m. 142±27 9.4±2.3 155
Median (range) 120 (60-360) 7 (4-30)
aControl vs anaplastic astrocytoma, glioblastoma and meningioma, P< 0.001. bMeningioma vs anaplastic astrocytoma
and glioblastoma, P< 0.05. cEleven specimens from patients aged 23-95 years with normal brains. dTwelve
specimens from patients aged 41-60 years with normal brains.
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Table 5 Levels of creatine kinase activity in various regions of normal human brain
Age (years)
Brain region 23 41 43 44 48 59 65 66 67 74 95
Cortex
Ug-1a 180 59 225 84 206 9.0 51 5.0 51 59 98
U mg-1a 12.8 4.5 12.7 6.4 13.2 0.8 5.8 0.5 5.4 4.5 5.9
Nucleus caudatus
Ug-l 208 13 218 23 110 22 28 3.0 n.d. 12 8.8
U mg-1 10.4 0.8 11.7 1.5 6.5 1.9 2.3 0.3 n.d. 0.8 0.6
White matter
Ug-1 161 135 148 59 84 44 58 12 n.d. 29 69
U mg-' 12.8 12 14.7 6.0 5.0 4.2 8.1 1.4 n.d. 2.2 7.3
Cerebellum
Ug-1 361 43 ND 7.0 235 6.0 22 3.0 17 4.0 5.0
U mg-, 16.6 3.1 ND 0.6 8.5 0.4 1.5 0.3 1.3 0.3 0.4
aActivity is expressed as units of activity per g of wet tissue and as units per mg of extracted protein.
Table 6 Total creatine kinase activity in human brain tumours
Tumour Survival Creative kinase activity
Case no. period
(months) U g-' Wet tissuea U mg-' Proteinb
Astrocytoma
1 96 4.2 0.1
2 108 31.0 1.2
3 c 31.0 2.6
4 c 6.7 6.2
Mean ± s.e.m. 18.2 ± 7.4 2.5 ± 1.3
Median (range) 18.8 (4.2-31) 1.9 (0.1-6.2)
Anaplastic astrocytoma
1 20 71.6 5.6
2 23 96.1 1.5
3 48 317.6 9.7
4 36 103.4 4.8
Mean ± s.e.m. 147.2 ± 57.2 5.4 ± 1.7
Median (range) 99.7 (71.6-317.6) 5.2 (1.5-9.7)
Glioblastoma
1 12 186.0 6.8
2 10 134.0 7.9
3 4 61.0 2.4
4 8 129.0 5.2
Mean ± s.e.m. 127.6 ± 25.6 5.6 ± 1.2
Median (range) 131.5 (61-186) 6.0 (2.4-7.9)
Meningioma
1 c 19.5 0.8
2 c 11.7 0.4
3 c 13.4 0.9
Mean±s.e.m. 14.9±2.3 0.72±0.15
Median (range) 13.4 (11.7-19.5) 0.82 (0.4-0.9)
Control tissued
Mean ± s.e.m. 74.8 ± 14.96 5.7 ± 0.97
Median (range) 54.5 (3.1-225) 5.18 (0.31-14.7)
aAstrocytomas vs anaplastic astrocytomas, P < 0.05; astrocytomas vs
glioblastomas, P < 0.05. bControl vs meningiomas, P< 0.05. cAfter 10 years
of follow-up, patients is still surviving and no recurrence has been registered.
dTwenty-two specimens from patients aged 41-67 years with normal brains.
Distribution of BPGP activity in normal brain and in
tumours
To compare the distribution of the enzymes with BPGP activity in
the various regions ofhuman brain and in brain tumours, the BPGP
activity was determined and the PGM/BPGP activity ratio was
calculated. As summarized in Table 4, the PGM/BPGP activity
ratio did not present significant differences between the various
regions of the normal brain, which indicates that the levels of the
enzymes with PGM activities and the enzymes with BPGP activi-
ties varied in parallel. Among the tumours, meningiomas presented
a significantly lower activity ratio (P < 0.01) as a consequence of
both the decrease ofthe PGM activity and the increase ofthe BPGP
activity, indicating that in these tumours, in addition to decreasing
PGM levels, there is an increase in the levels ofthe other enzymes
with BPGP activity (BPGM and BPGM-PGM hybrid).
Distribution of total CK activity in normal brain and in
tumours
Table 5 summarizes the levels of total CK activity in various
regions of human brain at different ages. As shown, wide vari-
ability is found. However, some general trends emerge. From 48
years of age, CK activity declines in all brain regions. The distrib-
ution of total CK activity in brain is non-uniform. Up to about 50
years of age cerebellum presents, in most cases, higherCK activity
than the other regions of the brain. With increasing age, the
cerebral cortex and the white matter tend to become the regions
with the highest CK levels.
Table 6 summarizes the levels of total CK activity in brain
tumours. As shown, among the astrocytic tumours, astrocytomas
possess lower CK content than anaplastic astrocytomas (P < 0.05)
and glioblastomas (P < 0.05) and, in addition, tend to possess
lower CK levels than normal brain, although the difference is not
statistically significant.
Distribution of CK isoenzymes in normal brain and in
tumours
The distribution ofCKisoenzymes in various regions ofhumanbrain
at different ages was determined by agarose gel electrophoresis.
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Figure 3 Electrophoretograms of CK isoenzymes in extracts of various regions of normal human brain. (A) Patient aged 23 years. (B) Patient aged 41 years.
(C) Patient aged 65 years. (D) Patient aged 95 years. 1, Cortex; 2, white matter; 3, nucleus caudatus; 4, cerebellum
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Figure 4 Electrophoretograms of CK isoenzymes in extracts of adult
human tissues. Lanes 1 and 8, skeletal muscle; lanes 2 and 7, heart; lanes
3-6, cortex, temporal lobe, hippocampus and cerebellum (hemisphere) from
a 23-year-old patient
Figure 3 shows some of the electrophoretograms. All specimens
showed BB-CK and one or two additional cathodic bands migrating
similarly to the dimeric and octameric forms of Mt-CK. Type MM-
CK was not detected in any ofthe specimens. In some extracts with
very high total CK activity, a faint band was visualized with an elec-
trophoretic mobility close to that of type MB-CK (Figure 4). This
band was not detected when phosphocreatine was omitted in the
staining mixture (not shown), which proved that it was not adenylate
kinase. As shown in Figure 5, the two cathodic bands were not
affected by incubation with anti M-CK antibodies, confirming that
they correspond to Mt-CK.
To confirm the distribution of CK isoenzymes in human brain,
tissue extracts were analysed by ion-exchange fast-liquid chro-
matography. As shown in Figure 6A, when heart extract analysed
as a control was chromatographed on a mono Q column, four
peaks were isolated. Peak I, not retained on the column, contains
MM-CK and Mt-CK (Leroux et al, 1977; Morin, 1977; Desjardins,
1982; Tsung, 1983). Peak II represents the CK fraction designated
as CK-Z (Leroux et al, 1977). It has been detected in extracts of
heart, skeletal muscle and brain (Leroux et al, 1977), and it is prob-
ably of mitochondrial origin (Desjardins, 1982; Desjardins and
Pesclovitch, 1983). Peak III contains type MB-CK, and peak IV
corresponds to type BB-CK (Leroux et al, 1977; Morin, 1977;
Desjardins, 1982; Tsung, 1983). Similar results were obtained
when the heart extract was chromatographed on a mono P column
1 2 3 4
Figure 5 Effect of M-CK antibodies on the CK electrophoretic bands
detected in extracts of human skeletal muscle and brain. 1, Muscle; 2,
muscle treated with M-CK antibodies; 3, brain (cortex); 4; brain (cortex)
treated with M-CK antibodies. Experimental conditions were those described
in Materials and methods
(not shown). In order to confirm the identity of the CK fractions
isolated by ion-exchange chromatography, the various peaks were
subjected to agarose gel electrophoresis. As shown in Figure 7,
peaks I, III and IV migrated as MM-, MB- and BB-CK, respec-
tively, and peak II migrated in a position anodic with respect to
MM-CK. Different electrophoretic patterns have been reported for
CK-Z. Leroux et al (1977) found two bands: one band that
remained at the origin and one band that migrated in a position
intermediate between the MM- and MB-CK isoenzymes.
Desjardins (1982) found only one band that migrated cathodically
relative to MM-CK and the application point.
Figure 6B shows the CK profile obtained when brain extract
was subjected to ion-exchange chromatography on a mono Q
column. As shown, only two peaks, corresponding to peak I and to
peak IV from heart extract, were eluted. No CK activity was
detected in the position corresponding to MB-CK. Therefore, it
was concluded that the band with a mobility similar to that ofMB-
CK detected by electrophoresis in some brain extracts was prob-
ably an artefact. Madsen (1972) found an atypical electrophoretic
CK form (CK-X) that was suposed to be generated from BB-CK
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Figure 6 FPLC separation of CK isoenzymes from human heart (A) and brain cortex (B) on a Mono Q column. Experimental conditions were those described
in Materials and methods
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Figure 7 Electrophoretic analysis of the CK peaks isolated by FPLC
separation. 1, Heart extract; 2, heart extract filtered through Sephadex G-25;
3, peak (Mono P column); 4, peak IlIl (Mono P column); 5, peak IV (Mono Q
column); 6, peak 11 (Mono Q column)
during preparation or storage. Chastain et al (1988) detected a
band migrating as MB-CK in a brain autopsy specimen and
showed that BB-CK extracted from human brain obtained at
surgery undergoes modification at 37°C, leaving an electro-
phoretic variant that migrates similarly to MB-CK.
As shown in Figure 4, the levels of Mt-CK were always lower
than the levels ofBB-CK. The proportion ofMt-CK relative to the
total CK activity could not be determined from the electrophoreto-
grams, as to detect the Mt-CK bands it was necessary to apply
large volumes ofthe extracts - over the limit ofproportionality of
the staining method. However, as all the applied samples had
similar total CK activity, a comparison between specimens was
possible. From this comparison, it could be deduced that the
proportion of Mt-CK in white matter was lower than in other
regions ofthe human brain.
Figure 8 shows the CK isoenzyme patterns of some ofthe brain
tumours analysed by agarose gel electrophoresis. Type BB-CK
was the only CK cytosolic isoenzyme found in tumour extracts; in
addition to which, one or two bands corresponding to Mt-CK were
detected. For the reasons indicated above, the proportion of Mt-
CK relative to the total CK activity could not be determined from
the electrophoretograms. From these data, it can be concluded that
in astrocytic tumours and in meninigiomas there were no qualita-
tive changes in the expression ofcytosolic CK subunits.
DISCUSSION
Our results show that normal brain from patients aged 23 to about
50 years of age presents higher CK than PGM activity. However,
with increasing age, the PGM activity remains constant while CK
activity declines. Up to about 50 years of age, cerebellum has
higher CK and PGM activity than the other regions of the brain;
this difference is not observed in older patients.
British Journal ofCancer (1997) 76(9), 1139-1149 0 CancerResearch Campaign 1997Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase andcreatine kinase in brain tumours 1147
+
2 3 4 5 6 7 8
0 0
9 10 11 12 13 14 15 16
0 .
17 18 19 20 21 22 23 24
Figure 8 Electrophoretograms of CK isoenzymes in extracts of human brain
tumours. Lanes 1, 8, 9, 16, 17 and 24, skeletal muscle; lanes 2, 7, 10, 15,18,
and 23, normal brain (cortex); lanes 11 and 12, astrocytomas; lanes 3, 4, 6
and 13, anaplastic astrocytomas; lanes 5 and 14, glioblastomas; lanes
19-22, meningiomas
With respect to the distribution ofPGM isoenzymes, our results
show that, although type BB-PGM is the main PGM form in adult
brain, brain tissue also exhibits type MM- and type MB-PGM.
These isoenzymes have also been detected by cellulose acetate
electrophoresis in ratbrain (Durany and Carreras, 1996) andby ion-
exchange chromatography in pig brain (Carreras et al, 1981). Using
Northern blot analysis, B-PGM mRNA but not M-PGM message
was detected in human (Shanske et al, 1987; Sakoda et al, 1988)
and in rat (CastelIa-Escola et al, 1990; Brocefno et al, 1995) brain.
But, as Schon and co-workers (Shanske et al, 1987; Sakoda et al,
1988) have indicated, alack ofdetection ofM-PGM transcript does
not exclude low transcription ofM-PGM message in the brain.
Most authors have reported that BB-CK is the only CK cytosolic
isoenzyme present in human brain based upon electrophoretic (Deul
and Van Breemen, 1964; Sjovall and Voigt, 1964; Dawson and Fine,
1967; Kumudavalli and Watts, 1968; Allard and Cabrol, 1970;
Smith, 1972; Klein et al, 1973; Ogunro et al, 1977; Petronia et al,
1980; Urdal et al, 1983; Chandler et al, 1984; Chastain et al, 1988),
chromatographic (Roberts et al, 1975; Tsung, 1976) and immuno-
logical techniques (Jockers-Wretou and Pfleiderer, 1975; Wevers et
al, 1981; Chandler et al., 1984; Chastain et al., 1988). However,
some authors have reported the presence of MM-CK. Some of the
reports (Murone and Ogotam, 1973; Mercer, 1974; Nealon and
Henderson, 1975; Goulle et al, 1979; Miller and Wei, 1985) should
bejudged with caution, as separation methods that did not differen-
tiate between MM-CK and Mt-CK were used, and non-inhibited
adenylate kinase could interfere (Klein and Jeunelot, 1978; Lyndsey
and Diamond, 1978; Desjardins, 1982; Urdal et al, 1983). But type
MM-CK has also been detected in human brain using immuno-
logical techniques (Lyndsey and Diamond, 1978; Heinbokel et al,
1982), and it has been isolated from human temporal lobe and
hippocampus (Hamburg et al, 1990); moreover, M-CK message has
been detected by these authors. We have not found type MM-CK
in any region of human brain, including the temporal lobe and
hippocampus. This fact does not exclude the presence ofMM-CK in
human brain, as very low levels of MM-CK (less than 7% of the
total CK activity) would not be detected in our electrophoretic
analysis. However, the absence of type MM-CK in the electro-
phoretograms of extracts of the temporal lobe and hippocampus
indicates that the very high levels of MM-CK (about 35% of the
total CK activity) found in these regions by Hamburg et al (1990)
were probably overestimated as a result ofpost-mortem artefacts, as
already suggested by others (Hemer et al, 1994). Our results
showing the presence of Mt-CK in the various regions of adult
human brain agree with the data from others on Mt-CK protein
(Weversetal, 1977, 1981; Petronia et al, 1980;Chandleret al, 1984)
and mRNA (Hass and Strauss, 1990; Payne and Strauss, 1994).
Zelter et al (1986), using immunoassay, found that astrocytomas
(grade I and II) and glioblastomas possessed lower BB-CK levels
than normal brain. Our results show that the astrocytic tumours
and the meningiomas had both lower total PGM and lower total
CK activity than the normal brain tissue. In other tumours, PGM
and CK activities did not vary in parallel. We have previously
found that colon, liver and lung adenocarcinomas, lung squamous
cell carcinomas and lung carcinoids had higher PGM activity than
the normal tissues (Durany et al, 1997). In contrast, colon and lung
adenocarcinomas and squamous cell carcinomas of the lung
presented lower CK activity than the normal tissue. No differences
were found between CK levels in hepatocarcinoma and those in
normal liver tissue, and lung carcinoids had greater CK activity
than normal lung tissue (Joseph et al, 1997).
In brain tumours, we have not detected qualitative changes in
the expression ofcytosolic CK subunits. These results are in agree-
ment with those of Ommen and Cheung (1974) who observed no
changes in the CK normal electrophoretic pattern in astrocytomas
of differing grades of malignancy. Rona et al (1972) found in
malignant brain tumours (astrocytoma and glioblastoma multi-
forme) a change in the CK isoenzyme phenotype towards the
muscle type pattern, and Tsung (1983) reported that a glioblastoma
multiforme contained twice as much MM-CK as BB-CK, as deter-
mined by ion-exchange chromatography. However, as discussed
above, it has to be considered that Mt-CK, present in both normal
brain and brain tumours, could interfere with MM-CK.
In brain tumours, we have also detected essentially the same
PGM isoenzyme pattern than that in normal brain, although the
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proportion ofMM and MB tended to decrease. Therefore it can be
concluded that in brain tumours any transition to the muscle-type
PGM phenotype does not occur and that, as a consequence, PGM
cannot be used as a good brain tumour marker, as previously
suggested by Omenn and Cheung (1974), Omenn and Hermodson
(1975). In agreement with our results, these authors found, almost
exclusively, type BB-PGM in meningiomas and benign astro-
cytomas and found the three PGM isoenzymes in highly malignant
astrocytomas and in a recurrent cerebellar haemangioblastoma.
However, as they did not detect type MB-PGM and MM-PGM in
the normal brain tissue, they concluded that neoplastic transforma-
tion activates greater expression of the type M-PGM subunit in
brain cells. We have clearly shown that MM- and MB-PGM iso-
enzymes are present in human brain and that, if their proportion
changes in brain tumours, then it is to decrease.
In a previous study (Joseph et al, 1996), we have found that the
enolase isoenzyme pattern in brain tumours changed significantly,
probably as a consequence of the different expression of enolase
subunits in the various cell populations of the brain. The small
changes, reported herein, in the PGM isoenzyme phenotype in
brain tumours cannot be easily explained, as no data are available
on the expression of PGM subunits in the different types of brain
cells. In rat brain, immunocytochemical studies have shown that
PGM is present in the cytoplasm of neurons, astrocytes, oligoden-
drocytes and endothelial cells, as well as in the nuclei of neurones
and astrocytes. However, the anti-PGM antibody used did not
differentiate between the type M- and the type B-PGM subunit
(Egea et al, 1992). Type BB-CK has been found in both human
neuronal and glial cells (Thompson et al, 1980; Pfeiffer et al, 1983;
Yoshimine et al, 1983; Worley et al, 1985).
ABBREVIATIONS
BPGP, 2,3-bisphosphoglycerate phosphatase; CK, creatine kinase;
PGM, phosphoglycerate mutase
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